Ethchlorvynol chemical structure
|ATC code |
|Molecular weight||144.598 g/mol|
|Legal status||Schedule IV|
|Routes of administration||Oral|
Along with expected sedative effects of relaxation and drowsiness ethchlorvynol can cause skin rashes, faintness, restlessness and euphoria. Early adjustment side effects can include nausea and vomiting, numbness, blurred vision, stomach pains and temporary dizziness. An overdose is marked by confusion, fever, peripheral numbness and weakness, reduced coordination and muscle control, slurred speech, reduced heartbeat.
It is addictive and after prolonged use can cause withdrawal symptoms including convulsions, hallucinations and memory loss. Due to these problems it is unusual for ethchlorvynol to be prescribed for periods exceeding seven days.
Ethchlorvynol is a member of the class of sedative-hypnotic tertiary carbinols such as methylparafynol. It is not a barbituric acid derivative. The systematic name of ethchlorvynol is usually given as ethyl 2-chlorovinyl ethynyl carbinol or 1-chloro-3-ethyl-1-penten-4-yl-3-ol. Its empirical formula is C7H9ClO. In the United States Abbott Laboratories used to sell it under the tradename Placidyl. Since Abbott and Banner Pharmacaps, which manufactured the generic version, discontinued production in 1999, ethchlorvynol is no longer available in the United States.
References and End Notes[edit | edit source]
- PubChem Substance Summary: Ethchlorvynol National Center for Biotechnology Information. Accessed 1 September 2005 (UTC)
- Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations Food and Drug Administration. Accessed 12 December 2005 (UTC)
- ^ Green List: Annex to the annual statistical report on psychotropic substances (form P) 23rd edition. August 2003. International Narcotics Board, Vienna International Centre. Accessed 1 September 2005 (UTC)
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|